Leighanne Oh

Leighanne Oh is a prominent biotech investor currently working at Ascenta Capital, having previously held a position as a biotech investor at Sofinnova Investments from 2019 to 2022. Her role at Sofinnova involved private equity investing in early- to late-stage biotech companies, as well as working on a therapeutics long/short equity public team in 2019. Sofinnova Investments is known for its focus on life sciences, particularly therapeutic drugs, and manages approximately $3.0 billion in assets.1

Education and Early Career

Leighanne holds both a Bachelor of Science in Engineering (B.S.E.) in Biomedical Engineering and a Master of Science (M.S.) in Biomedical Engineering from Duke University, where she was a Bill and Melinda Gates Millennium Scholar. Her academic research included work at Michael Lynch's lab at Duke.1

Before her tenure at Sofinnova, she worked as a Healthcare Investment Banking Analyst at Jefferies and had experience in various roles, including as an Advanced Manufacturing/Operations Engineer at GE Healthcare and a Research Analyst at NASA Langley Research Center.1

Professional Affiliations

In addition to her investment roles, Leighanne is actively involved in the biotech community and serves on the Galien Advisory Board, contributing to discussions and initiatives in the life sciences sector.2